Logotipo de Valence
populares
Iniciar sesión
Loading data for ADMA — first visit, this takes a few seconds.

Añadir a la lista de seguimiento

ADMA Biologics Inc.

NasdaqGM: ADMA · Precio en tiempo real · USD
10.05
+0.51 (5.35%)
Al cierre: Aug 19, 2026, 2:34 PM
10.05
+0.00%
Fuera de horario: 4:43 PM

ADMA Biologics Inc. (ADMA) Stock Price, Analysis & Data

5.35%
Precio de compran/a
Capitalización de mercado2.25B
Ingresos (TTM)512.28M
Beneficio neto (TTM)168.96M
Beta0.77
EPS (TTM)0.7
Ratio PER (TTM)14.36
Adelante PE10.23
P/B (TTM)5.55
P/S (TTM)4.39
Earnings DateNov 4, 2026
Precio de ventan/a
Volumen2,688,853
Volumen medio (20D)3,075,372
Abierto9.76
Anterior Cerrar9.54
Rango del día9.70 - 10.12
Rango de 52 semanas7.21 - 20.46
analistan/a
Precio objetivon/a
Dividendosn/a
Fecha ex dividendon/a

Acerca de ADMA

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodef...

[Leer más]
Industria Biotechnology
Sector Healthcare
IPO Fecha Oct 17, 2013
Empleados 640
Bolsa de Valores NasdaqGM
Símbolo bursátil ADMA
Sitio web https://www.admabiologics.com
Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de ADMA Biologics fueron 510.17M, un aumento de 19.63% en comparación con 426.45M del año anterior. Las ganancias fueron 146.93M, una disminución de -25.67%.

Estados financieros

Sorpresa de resultados

ADMA Biologics ha publicado sus resultados trimestrales en Aug 5, 2026:
  • Ingresos de $124.39M falla las estimaciones por $0, con 1.98% Crecimiento interanual.
  • EPS de 0.17 supera las estimaciones en 0.01, con 21.43% Crecimiento interanual.

    • Próxima publicación de resultados

    Está previsto que ADMA Biologics Inc. publique sus resultados el Nov 4, 2026, durante el horario de mercado.
    Los analistas proyectan ingresos de ... Actualizar
    news image

    1 semana hace · Zacks

    ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness

    ADMA Biologics matches earnings estimates, misses on revenues and maintains its 2026 outlook as strong Asceniv growth offsets continued pressure on Bivigam.

    news image

    1 semana hace · GuruFocus.com

    ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: Ascentiv Surges 24% as Gross ...

    ADMA Biologics Inc (ADMA) delivers strong Q2 2026 results with record Ascentiv growth and robust cash generation, despite persistent competitive pressures in the standard IG market.

    news image

    1 semana hace · MarketBeat

    ADMA Biologics Q2 Earnings Call Highlights

    ADMA Biologics (NASDAQ:ADMA) reported second-quarter revenue growth of 2% as increased sales of its ASCENIV immune globulin product offset pressure on BIVIGAM in the standard immunoglobulin market. Th...

    news image

    2 semanas hace · Zacks

    Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note

    Adma Biologics (ADMA) closed the most recent trading day at $8.46, moving 2.42% from the previous trading session.

    news image

    3 semanas hace · Zacks

    Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?

    Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness o...

    Página 1 de 2